Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Interest Expenses (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Interest Expenses over the past 12 years, most recently at $3.3 million for Q4 2025.

  • Quarterly results put Interest Expenses at $3.3 million for Q4 2025, up 534.82% from a year ago — trailing twelve months through Dec 2025 was $4.9 million (up 121.61% YoY), and the annual figure for FY2025 was $4.9 million, up 125.22%.
  • Interest Expenses for Q4 2025 was $3.3 million at Viridian Therapeutics, Inc.\DE, up from $560000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for VRDN hit a ceiling of $3.3 million in Q4 2025 and a floor of $3000.0 in Q4 2021.
  • Median Interest Expenses over the past 5 years was $515500.0 (2024), compared with a mean of $562000.0.
  • Biggest five-year swings in Interest Expenses: plummeted 98.33% in 2021 and later surged 5500.0% in 2022.
  • Viridian Therapeutics, Inc.\DE's Interest Expenses stood at $3000.0 in 2021, then surged by 5500.0% to $168000.0 in 2022, then skyrocketed by 138.1% to $400000.0 in 2023, then grew by 29.25% to $517000.0 in 2024, then skyrocketed by 534.82% to $3.3 million in 2025.
  • The last three reported values for Interest Expenses were $3.3 million (Q4 2025), $560000.0 (Q3 2025), and $514000.0 (Q2 2025) per Business Quant data.